GSA Capital Partners LLP Sells 716,698 Shares of Nektar Therapeutics (NASDAQ:NKTR)

GSA Capital Partners LLP lessened its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 77.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 214,245 shares of the biopharmaceutical company’s stock after selling 716,698 shares during the period. GSA Capital Partners LLP owned 0.12% of Nektar Therapeutics worth $279,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. SG Americas Securities LLC boosted its holdings in Nektar Therapeutics by 30.4% in the third quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 22,285 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Nektar Therapeutics by 66.0% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after purchasing an additional 1,634,046 shares in the last quarter. Millennium Management LLC grew its position in Nektar Therapeutics by 56.1% in the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after purchasing an additional 1,674,924 shares during the period. Armistice Capital LLC bought a new stake in Nektar Therapeutics during the 2nd quarter valued at $1,037,000. Finally, Samlyn Capital LLC acquired a new position in Nektar Therapeutics during the second quarter worth $11,728,000. 75.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

NKTR has been the subject of a number of analyst reports. Piper Sandler began coverage on shares of Nektar Therapeutics in a report on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective for the company. BTIG Research reiterated a “buy” rating and set a $4.00 price target on shares of Nektar Therapeutics in a research note on Monday, September 30th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $3.50.

Nektar Therapeutics Stock Performance

Shares of NKTR stock opened at $1.05 on Friday. The company has a market capitalization of $193.68 million, a price-to-earnings ratio of -1.25 and a beta of 0.61. Nektar Therapeutics has a 52-week low of $0.42 and a 52-week high of $1.93. The company has a 50-day simple moving average of $1.27 and a two-hundred day simple moving average of $1.31.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.